GlassScriptPhysician profile
Samer Alsidawi
NPI 1932455896
$1,978.50
in general payments reported to CMS, 2019-2025
27 companies · $687 in 2025
The $687 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.94 · 2020: $78.22 · 2021: $59.35 · 2022: $96.67 · 2023: $419 · 2024: $580 · 2025: $687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,649 · Education: $37.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,649.30 |
| Education | $37.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $428.38 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $289.91 | 2021-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $211.87 | 2022-2023 | Epkinly, Imbruvica |
| Pfizer INC. | $136.74 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $118.22 | 2021-2025 | Libtayo |
| Daiichi Sankyo INC. | $115.67 | 2020-2025 | Vanflyta |
| Glaxosmithkline, LLC. | $78.97 | 2024-2025 | Ojjaara |
| Boston Scientific Corporation | $57.94 | 2019 | |
| Aveo Pharmaceuticals, INC. | $56.28 | 2024-2025 | |
| Amgen INC. | $49.08 | 2021-2022 | |
| Emd Serono, INC. | $46.85 | 2024 | |
| Sirtex Medical INC | $45.97 | 2024-2025 | Sir-Spheres Microspheres |
| Celgene Corporation | $39.81 | 2023-2024 | Pomalyst |
| Agios Pharmaceuticals, INC. | $39.61 | 2024-2025 | Pyrukynd |
| Janssen Biotech, INC. | $35.00 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $30.03 | 2023-2025 | Yescarta |
| Servier Pharmaceuticals LLC | $23.26 | 2023 | |
| Eisai INC. | $22.50 | 2023 | |
| Adaptive Biotechnologies Corporation | $20.99 | 2023 | Clonoseq |
| Seagen INC. | $20.25 | 2023 | Padcev |
| Springworks Therapeutics, INC. | $20.25 | 2024 | Ogsiveo |
| Pharmaessentia USA Corporation | $19.14 | 2023 | Besremi |
| Array Biopharma INC | $18.09 | 2025 | Braftovi, Lorbrena, Mektovi |
| Astrazeneca Pharmaceuticals LP | $16.08 | 2025 | |
| Merck Sharp & Dohme LLC | $13.00 | 2020 | |
| Rigel Pharmaceuticals, INC. | $12.40 | 2023 | Rezlidhia, Tavalisse |
| E.R. Squibb & Sons, L.L.C. | $12.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samer Alsidawi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.